Noxa upregulation and 5-gene apoptotic biomarker panel in colorectal cancer.

European Journal of Clinical Investigation
Vivian KosmidouAlexander Pintzas

Abstract

NOXA and MCL1 are involved in the intrinsic pathway of apoptosis, where Noxa selectively binds to MCL1 and prevents it from inhibiting apoptosis. Both factors are considered as potential tumour biomarkers, while MCL1 has attracted interest as target in cancer. The purpose of this study was to investigate the expression of NOXA and MCL1 in 160 CRC tumour samples, to investigate their significance, also in combination with IAPs, DR5 expression and KRAS gene mutations in CRC. Fresh frozen colorectal tissue was obtained from patients undergoing surgery for CRC. Real-time quantitative PCR was performed for the determination of mRNA expression levels. Protein expression was determined immunohistochemically. Differences in the mRNA expression profile were evaluated with the nonparametric Wilcoxon signed ranks test. Statistical analysis was performed with the use of Mann-Whitney U test and receiver-operating characteristic (ROC) curve. NOXA was found to be overexpressed in CRC tumours (P < .0001), even from early stage. Moreover, NOXA/MCL1 mRNA expression was significantly elevated in tumour samples compared to normal pairs (P < .0001). ROC curve analysis showed that both NOXA expression and its combination with Mcl1 expression have fa...Continue Reading

References

Jul 25, 2003·Oncogene·Agneta K JanssonXiao-Feng Sun
Oct 5, 2006·Cancer Research·Jian-Zhong QinBrian J Nickoloff
Dec 7, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jean-Simon DialloFred Saad
Sep 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Frank A SinicropeHarold E Windschitl
Apr 18, 2009·Molecular Cancer Therapeutics·Paula HauckGeoffrey W Krystal
Jan 9, 2010·European Journal of Clinical Investigation·I SimeraD G Altman
Jun 15, 2010·FEBS Letters·Luke W ThomasSteven W Edwards
Jun 24, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Donal P McLornanPatrick G Johnston
Apr 22, 2011·Nature Reviews. Cancer·Nicola McCarthy
Aug 20, 2011·Expert Opinion on Investigational Drugs·Bridget A QuinnPaul B Fisher
Feb 2, 2012·Nature Reviews. Drug Discovery·Simone Fulda, Domagoj Vucic
Mar 5, 2013·Oncotarget·James A McCubreyZoya N Demidenko
Jul 12, 2014·BioMed Research International·Mohamed HassanNoriaki Sakuragi
Dec 19, 2015·Journal of Cellular Physiology·Kazutaka OuchiHajime Hosoi
Aug 31, 2016·World Journal of Gastrointestinal Oncology·Aman M Abraha, Ezra B Ketema
Mar 16, 2017·British Journal of Haematology·Elisabeth HöringHeiko van der Kuip
May 4, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Angie M Torres-AdornoNaoto T Ueno
Jun 7, 2018·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·Jingyi WuDong Hua
Aug 6, 2018·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Ya-Hui BaiXian-Zhi Liu
Nov 16, 2019·Nature Communications·Joan MonteroRizwan Haq

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis